Streetbeat News

Stock Prices

SPY

TLT

Lauren Goodwin, Chief Market Strategist at New York Life Investments, believes the equity markets have room to grow until the labor market weakens, despite recession concerns. Her comments come amid mixed signals about the economy and public sentiment.

Portfolio Pulse from Benzinga Neuro

June 05, 2024 | 11:22 am

CANF

Can-Fite Biopharma announced that its Phase 3 study for Namodenoson, a treatment for advanced liver cancer, is now recruiting at 31 medical centers. Namodenoson has received Orphan Drug status from both the FDA and the European Medicines Agency, as well as FDA Fast Track status. Additionally, a compassionate use program is ongoing in Israel and Romania.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:18 am

CPB

Campbell Soup shares are trading higher after the company reported better-than-expected Q3 results and issued FY24 guidance above estimates.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:17 am

CPB

Campbell Soup Company (CPB) has projected a 6.5%-7% growth in adjusted EBIT for the fiscal year 2024.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:17 am

CPB

Campbell Soup Company has raised its fiscal year 2024 adjusted earnings per share (EPS) guidance to a range of $3.07 to $3.10, up from the previous estimate of $3.03.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:17 am

AEI

JOB

RDGL

Insiders are buying shares of Vivos Inc. (OTC:RDGL), Alset Inc. (NASDAQ:AEI), and GEE Group Inc. (NYSE:JOB), indicating their confidence in these companies. Vivos' CEO bought 50,000 shares, Alset's CEO acquired 20,312 shares, and GEE Group's Director purchased 300,000 shares.

Portfolio Pulse from Avi Kapoor

June 05, 2024 | 11:16 am

GWAV

Greenwave Technology is confident in exceeding its revenue guidance of $40M for 2024, driven by increased volume and higher prices of steel and copper. Copper prices hit an all-time high in May 2024.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:12 am

ALT

Altimmune, Inc. (NASDAQ:ALT) presented new data on pemvidutide's benefits for liver disease and obesity at the EASL Congress. The data showed significant improvements in liver health and body composition, suggesting pemvidutide's potential as a differentiated treatment for MASH and obesity.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:12 am

HROW

Harrow (NASDAQ:HROW) announced positive results from its ESSENCE-2 open-label extension clinical study for VEVYE, a cyclosporine ophthalmic solution for treating dry eye disease. The study demonstrated significant improvements in efficacy endpoints and high patient satisfaction, with minimal adverse events.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:10 am

MITQ

Moving iMage Technologies shares are trading higher after the company was awarded a multi-million dollar contract.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:09 am